Phlow vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Phlow raised $37M Series C in July 2025 and holds $600M+ in government contracts including a $354M BARDA contract; manufactures critical active pharmaceutical ingredients and finished drug forms entirely within the U.S.
About
Phlow is a public benefit pharmaceutical company that develops and manufactures critical active pharmaceutical ingredients (APIs) and finished dosage forms entirely within the United States. Its mission is to strengthen national medicine supply chains by producing drugs domestically, reducing dependence on foreign API suppliers — primarily in China and India — that supply the majority of the U.S. medicine supply. Phlow''s manufacturing model uses continuous flow chemistry and advanced automation to produce APIs at lower cost and higher quality consistency than traditional batch manufacturing.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.